SCHEMBL6230110

SCHEMBL6230110

COc1cc(/C=C/c2ccccc2)cc(O)c1CC=C(C)C

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 4/20 0.61
PPARA Q07869 4/20 0.61
CYP19A1 P11511 6/20 0.60
ALOX5 P09917 4/20 0.60
PTGS2 P35354 3/20 0.60
MAOA P21397 1/20 0.59
MAOB P27338 1/20 0.59
ABCB1 P08183 2/20 0.59
TUBB1 Q9H4B7 2/20 0.55
TUBB4A P04350 1/20 0.51
TUBB P07437 1/20 0.51
TUBA3C P0DPH7 1/20 0.51
TUBA1B P68363 1/20 0.51
TUBA4A P68366 1/20 0.51
TUBB4B P68371 1/20 0.51
TUBB3 Q13509 1/20 0.51
TUBB2A Q13885 1/20 0.51
TUBB8 Q3ZCM7 1/20 0.51
TUBA3E Q6PEY2 1/20 0.51
TUBA1A Q71U36 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6230114 1.00 PPARG (0.61) PPARGPPARACYP19A1ALOX5PTGS2
SCHEMBL16199999 0.95 ABCB1 (0.57) PPARGPPARACYP19A1ALOX5PTGS2
SCHEMBL6228549 0.92 ABCB1 (0.60) PPARGPPARACYP19A1ALOX5PTGS2
SCHEMBL6228547 0.92 ABCB1 (0.60) PPARGPPARACYP19A1ALOX5PTGS2
SCHEMBL16199962 0.89 PPARG (0.80) PPARGPPARAMAOBPPARD
SCHEMBL16200005 0.89 MAOB (0.76) PPARGPPARACYP19A1ALOX5PTGS2
SCHEMBL16199920 0.88 CYP19A1 (0.72) PPARGPPARACYP19A1ALOX5PTGS2
SCHEMBL16200144 0.88 MAOA (0.62) PPARGPPARACYP19A1ALOX5PTGS2
SCHEMBL16200113 0.87 ALOX5 (0.52) PPARGPPARACYP19A1ALOX5PTGS2
SCHEMBL16199906 0.87 CYP19A1 (0.58) PPARGPPARACYP19A1ALOX5PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119925454-A Application of cajan leaf in rats with chronic myelosuppression caused by MTX 浙江中医药大学 2025-05-06 CN disclosed
US-11795127-B2 Processes for the preparation of ortho-allylated hydroxy aryl compounds MCMASTER UNIVERSITY (CA) 2023-10-24 US disclosed
US-11795127-B2 Processes for the preparation of ortho-allylated hydroxy aryl compounds MCMASTER UNIVERSITY (CA) 2023-10-24 US disclosed
US-20230113567-A1 PROCESSES FOR THE PREPARATION OF ORTHO-ALLYLATED HYDROXY ARYL COMPOUNDS MCMASTER UNIVERSITY (CA) 2023-04-13 US disclosed
US-20210380513-A1 PROCESSES FOR THE PREPARATION OF ORTHO-ALLYLATED HYDROXY ARYL COMPOUNDS MCMASTER UNIVERSITY (CA) 2021-12-09 US disclosed
WO-2021237371-A1 PROCESSES FOR THE PREPARATION OF ORTHO-ALLYLATED HYDROXY ARYL COMPOUNDS MCMASTER UNIVERSITY (CA) 2021-12-02 WO disclosed
US-10760062-B2 Biosynthesis of phenylpropanoids and phenylpropanoid derivatives EVOLVA SA (CH) 2020-09-01 US disclosed
EP-2796442-B1 CAJANINE STRUCTURE ANALOGOUS COMPOUND, PREPARATION METHOD AND USE INST MED BIOTECHNOLOGY CAMS (CN) 2019-03-27 EP disclosed
US-20180142216-A1 Biosynthesis of Phenylpropanoid and Dihydrophenylpropanoid Derivatives DANSTAR FERMENT AG (CH) 2018-05-24 US disclosed
US-20180142216-A1 Biosynthesis of Phenylpropanoid and Dihydrophenylpropanoid Derivatives DANSTAR FERMENT AG (CH) 2018-05-24 US disclosed
US-20140371232-A1 CAJANINE STRUCTURE ANALOGOUS COMPOUND, PREPARATION METHOD AND USE INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2014-12-18 US disclosed
EP-2796442-A1 CAJANINE STRUCTURE ANALOGOUS COMPOUND, PREPARATION METHOD AND USE Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CN) 2014-10-29 EP disclosed
EP-1311257-B1 COMPOSITIONS CONTAINING HYPOGLYCEMICALLY ACTIVE STILBENOIDS INSMED INC (US) 2005-04-27 EP disclosed
EP-1311257-A2 COMPOSITIONS CONTAINING HYPOGLYCEMICALLY ACTIVE STILBENOIDS Insmed Incorporated (US) 2003-05-21 EP disclosed
US-6552085-B2 For lowering blood glucose in a mammal INSMED INCORPORATED 2003-04-22 US disclosed
US-6410596-B1 FOR LOWERING BLOOD GLUCOSE IN A MAMMAL INSMED INCORPORATED 2002-06-25 US disclosed
US-20020058707-A1 COMPOSITIONS CONTAINING HYPOGLYCEMICALLY ACTIVE STILBENOIDS INSMED INCORPORATED 2002-05-16 US disclosed
US-20020058701-A1 Compositions containing hypoglycemically active stilbenoids SHAMAN PHARMACEUTICALS 2002-05-16 US disclosed
WO-2002013811-A2 COMPOSITIONS CONTAINING HYPOGLYCEMICALLY ACTIVE STILBENOIDS INSMED INCORPORATED (US) 2002-02-21 WO disclosed
WO-2002014252-A2 COMPOSITIONS CONTAINING HYPOGLYCEMICALLY ACTIVE STILBENOIDS INSMED INCORPORATED (US) 2002-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230113567-A1 PROCESSES FOR THE PREPARATION OF ORTHO-ALLYLATED HYDROXY ARYL COMPOUNDS ADH1A, ADH1C, AHR PPARG 543/4885PPARA 231/4885CYP19A1 77/4885
US-20020058707-A1 COMPOSITIONS CONTAINING HYPOGLYCEMICALLY ACTIVE STILBENOIDS SLC5A2, SLC5A1, SLC2A1 PPARG 1187/4885PPARA 479/4885CYP19A1 207/4885
US-20210380513-A1 PROCESSES FOR THE PREPARATION OF ORTHO-ALLYLATED HYDROXY ARYL COMPOUNDS ADH1A, ADH1C, AHR PPARG 543/4885PPARA 231/4885CYP19A1 77/4885
US-20140371232-A1 CAJANINE STRUCTURE ANALOGOUS COMPOUND, PREPARATION METHOD AND USE ACHE, GAP43, LNPK PPARG 3419/4885PPARA 2766/4885CYP19A1 1479/4885
US-11795127-B2 Processes for the preparation of ortho-allylated hydroxy aryl compounds ADH1A, ADH1C, AHR PPARG 543/4885PPARA 231/4885CYP19A1 77/4885
US-20020058701-A1 Compositions containing hypoglycemically active stilbenoids SLC5A2, SLC5A1, SLC2A1 PPARG 1187/4885PPARA 479/4885CYP19A1 207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.